Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Adicet Bio (Nasdaq: ACET) announced inducement grants to three new employees hired in October 2024. The company granted non-qualified stock options to purchase 59,800 shares at an exercise price of $1.28 per share. The vesting schedule includes 25% after one year, with the remaining 75% vesting monthly over three years. These awards were granted under Adicet's 2022 Inducement Plan, approved by the compensation committee as material inducement for employment in accordance with Nasdaq Rule 5635(c)(4).
Adicet Bio (Nasdaq: ACET) ha annunciato concessioni di incentivo per tre nuovi dipendenti assunti nell'ottobre 2024. L'azienda ha concesso opzioni su azioni non qualificate per acquistare 59.800 azioni a un prezzo di esercizio di $1,28 per azione. Il programma di maturazione prevede il 25% dopo un anno, con il restante 75% che matura mensilmente nel corso di tre anni. Questi premi sono stati concessi nell'ambito del Piano di Induzione 2022 di Adicet, approvato dal comitato per la compensazione come incentivo materiale per l'impiego in conformità con la Regola 5635(c)(4) del Nasdaq.
Adicet Bio (Nasdaq: ACET) anunció concesiones de incentivo a tres nuevos empleados contratados en octubre de 2024. La compañía otorgó opciones sobre acciones no calificadas para comprar 59,800 acciones a un precio de ejercicio de $1.28 por acción. El cronograma de adquisición incluye el 25% después de un año, con el 75% restante acumulándose mensualmente durante tres años. Estos premios se otorgaron bajo el Plan de Inducción 2022 de Adicet, aprobado por el comité de compensación como incentivo material para el empleo de acuerdo con la Regla 5635(c)(4) de Nasdaq.
Adicet Bio (Nasdaq: ACET)는 2024년 10월에 채용된 세 명의 신입 사원에게 유인 보상을 발표했습니다. 회사는 59,800주의 비정규 주식 매입 옵션을 $1.28의 행사가로 부여했습니다. 베스팅 일정은 1년 후 25%가 부여되며, 나머지 75%는 3년에 걸쳐 매달 부여됩니다. 이러한 보상은 Nasdaq 규정 5635(c)(4)에 따라 고용 유인을 위한 물질적 유인으로 보상위원회에서 승인된 Adicet의 2022 유인 계획에 따라 부여되었습니다.
Adicet Bio (Nasdaq: ACET) a annoncé des attributions incitatives pour trois nouveaux employés recrutés en octobre 2024. La société a accordé des options d'achat d'actions non qualifiées pour acquérir 59 800 actions à un prix d'exercice de $1,28 par action. Le calendrier d'acquisition comprend 25% après un an, le reste de 75% s'acquérant mensuellement sur une période de trois ans. Ces récompenses ont été accordées dans le cadre du Plan d'Induction 2022 d'Adicet, approuvé par le comité des rémunérations comme incitation matérielle à l'emploi conformément à la règle 5635(c)(4) du Nasdaq.
Adicet Bio (Nasdaq: ACET) hat Anreizvergaben an drei neue Mitarbeiter angekündigt, die im Oktober 2024 eingestellt wurden. Das Unternehmen hat nicht qualifizierte Aktienoptionen für den Kauf von 59.800 Aktien zu einem Ausübungspreis von $1,28 pro Aktie gewährt. Der Vesting-Plan umfasst 25% nach einem Jahr, wobei die restlichen 75% monatlich über drei Jahre ausgezahlt werden. Diese Auszeichnungen wurden im Rahmen von Adicets 2022 Inducement Plan gewährt, der vom Vergütungsausschuss als materieller Anreiz für die Beschäftigung gemäß der Nasdaq-Regel 5635(c)(4) genehmigt wurde.
- None.
- None.
Three individuals were hired by Adicet in October 2024. In the aggregate, Adicet granted new hires non-qualified stock options to purchase 59,800 shares of Adicet’s common stock with an exercise price of
All of the above-described awards were granted outside of Adicet’s stockholder-approved equity incentive plans pursuant to Adicet’s 2022 Inducement Plan (the Inducement Plan), which was adopted by the board of directors in January 2022 and subsequently amended in January 2023. The awards were authorized by the compensation committee of the board of directors, which is comprised solely of independent directors, as a material inducement to the employees entering into employment with Adicet in accordance with Nasdaq Listing Rule 5635(c)(4).
About Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241031738321/en/
Adicet Bio, Inc.
Investor and Media Contacts
Investors:
Anne Bowdidge
abowdidge@adicetbio.com
Janhavi Mohite
Precision AQ
212-362-1200
janhavi.mohite@precisionaq.com
Media:
Kerry Beth Daly
kbdaly@adicetbio.com
Source: Adicet Bio, Inc.
FAQ
What was the exercise price for Adicet Bio's (ACET) inducement grants in October 2024?
How many shares were included in Adicet Bio's (ACET) October 2024 inducement grants?